Disease · MONDO_0003441

dystonic disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. dystonic disorder. Diseases, record MONDO_0003441. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003441

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: dystonic disorder; Open Targets
Open Targets ID: MONDO_0003441; Open Targets
Other names: Dystonic movements, dystonia; Open Targets
Disease Ontology: DOID:543; Disease Ontology
MeSH: D020821; MeSH
NCI Thesaurus: C34563; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 12 drugs, from PMDA and TTD; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RIMABOTULINUMTOXINB	CHEMBL1201569	Protein	Approval	PMDA	2	1	1	Drugs and targets
TRIHEXYPHENIDYL	CHEMBL1490	Small molecule	Approval	TTD	2	1	1	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
COBALAMIN	CHEMBL4297272	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
PYRIDOXINE	CHEMBL1364	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
DRONABINOL	CHEMBL465	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
MEXILETINE	CHEMBL558	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NABIXIMOLS	CHEMBL3833333	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
DEUTETRABENAZINE	CHEMBL3137326	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets15

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CNR1	Cannabinoid receptor 1	2	Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/1268	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	2	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 3	https://conductscience.org/library/genes/6616	Drugs and targets
CHRM1	Muscarinic acetylcholine receptor M1	1	Muscarinic acetylcholine receptor M1 antagonist	Approval	https://conductscience.org/library/genes/1128	Drugs and targets
SCN10A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6331	Drugs and targets

1 to 10 of 15

See all 15 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00208091	Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia	Phase 4	16	2014-05-09	Focal Dystonia	RIMABOTULINUMTOXINB	Its record names the disease	ClinicalTrials.gov
NCT04173260	An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia	Phase 1/2	15	2024-06-12	Dystonia, Primary	DEUTETRABENAZINE	Its record names the disease	ClinicalTrials.gov
NCT06386848	Strategy to Adapt Botulinum Toxin Doses in Dystonia		100		Dystonia	ONABOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT00909883	Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)	Phase 3	45		Parkinson's Disease, Foot Dystonia	ONABOTULINUMTOXINA	Open Targets' reading of its record	ClinicalTrials.gov
NCT03790345	Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics	Phase 2/3	45		Schizophrenia, Drug Induced Movement Disorder, Unspecified, Oxidative Stress	COBALAMIN, PYRIDOXINE	Its record names the disease	ClinicalTrials.gov
NCT05627921	The Effect of Botulinum Toxin and ESWT Applications on Spasticity and Functionality in Cerebral Palsy Patients	Not applicable	40		Cerebral Palsy, Spastic	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov
NCT00122044	Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects	Phase 2	35		Dystonia	TRIHEXYPHENIDYL	Its record names the disease	ClinicalTrials.gov
NCT00001784	Mexiletine for the Treatment of Focal Dystonia	Phase 2	24		Blepharospasm, Dystonia, Spasm	MEXILETINE	Its record names the disease	ClinicalTrials.gov
NCT01433757	Ampicillin for DYT-1 Dystonia Motor Symptoms	Phase 1	2		DYT-1, Dystonia	AMPICILLIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
29102441	RESULT	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003441

GET https://conductscience.org/api/diseases/v1/MONDO_0003441/drugs

API reference For AI assistants